Summary by Moomoo AI
DEKI PHARMACEUTICALS CO., LTD. ANNOUNCED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023. REVENUE FOR THE REPORTING PERIOD DECREASED COMPARED TO THE SAME PERIOD LAST YEAR, MAINLY DUE TO LOWER REVENUES IN MAINLAND CHINA, INCLUDING VOLUNTARY REDUCTIONS IN SIVIO® (SELENISO) PRICES, ONE-TIME NEGATIVE SALES ADJUSTMENTS, AND COMMERCIALIZATION COOPERATION WITH JOHNSON PHARMACEUTICALS. R&D costs and sales and distribution expenses decreased, reflecting the Company's strategy of reducing capital efficiency. The loss for the year was reduced compared to the previous year and amendments were made to the existing articles of association and the rules of association. In the future, the company will invest heavily in assets with global rights and will not distribute dividends. The Annual General Meeting will be held on 14 June 2024.